Riskpilot← Back to searchSign inGet full accessEMRIVA AB
ABDissolvedOrg 5592421472Medical specialists activities · NACE 8622Est. 20201 employees
Revenue 2024
SEK 340K
-20% vs 2023
EBITDA margin
80.2%
-19% vs 2023
Equity ratio
95.5%
Financial strength
Net profit 2024
SEK 215K
-20% vs 2023
| Revenue | SEK 340K | -20% |
| EBITDA | SEK 273K | -19% |
| Net profit | SEK 215K | -20% |
| Total assets | SEK 352K | -6% |
| Equity | SEK 337K | +2% |
| Employees | 1 | — |
Legal name
EMRIVA AB
Org number
5592421472
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
13 februari 2020
Share capital
SEK 25 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanterna
Company purpose
Bolagets ska bedriva radiologisk diagnostik, medicinsk forskning, utveckling och utbildning samt därmed förenlig verksamhet.
Address
Email
info@bolagspartner.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 230 | 350 | 400 | 422 | 340 |
| Staff expenses | — | — | −32 | −28 | −17 |
| EBITDA | 153 | 291 | 311 | 338 | 273 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 153 | 291 | 311 | 338 | 273 |
| Net financials | — | — | — | −0 | −1 |
| Profit before tax | 153 | 291 | 311 | 338 | 271 |
| Tax | −33 | −60 | −64 | −70 | −56 |
| Net profit | 120 | 231 | 247 | 268 | 215 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 163 | 300 | 309 | 374 | 352 |
| Equity | 145 | 256 | 273 | 331 | 337 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 18 | 44 | 36 | 43 | 16 |
| Total debt | 18 | 44 | 36 | 43 | 16 |
EBITDA margin
80.2%
This company
15.8%
Market median
+408% vs market
20202024
Equity ratio
95.5%
This company
38.2%
Market median
+150% vs market
20202024
Return on equity
63.9%
This company
18.4%
Market median
+247% vs market
20202024
Net profit margin
63.3%
This company
8.1%
Market median
+681% vs market
20202024
Asset turnover
0.96×
This company
1.12×
Market median
+14% vs market
20202024
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-02-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2025 | |
| Deputy Board Member | 2025 | |
| Board of Directors | 2025 | |
| Former (4) | ||
| Board of Directors | 2022 – 2025 | |
| Chairman | 2022 – 2025 | |
| Board of Directors | 2022 – 2025 | |
| Board of Directors | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of EMRIVA AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mats Skanke Edström-Barup | Board of Directors | 0 companies |
| Nils Henrik Kristoffer Svensson | Deputy Board Member | 0 companies |
| Elna-Marie Boel Larsson | Chairman | 0 companies |
| Lina Anna Elisabeth Nordström | Deputy Board Member | 0 companies |
| Karl-Johan Staffan Tångby | Board of Directors | 0 companies |
| Lars Anders Sune Larsson | Board of Directors | 0 companies |
| Kerstin Else Maria Edström Barup | Board of Directors | 0 companies |